Achieve Life Sciences to Showcase Innovations at Key Conferences
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a pioneering force in the field of specialty pharmaceuticals, is set to engage with investors through two influential conferences. This participation is part of its ongoing commitment to advance treatments for nicotine dependence and making strides in smoking cessation strategies.
Details of Upcoming Conferences
Rick Stewart, the CEO of Achieve Life Sciences, will be involved in valuable discussions at the following major events:
H.C. Wainwright 27th Annual Global Investment Conference
This conference is scheduled for September 8, where Stewart will join a fireside chat led by equity research analyst Brandon Folkes. This event will provide an opportunity to explore Achieve's innovative approaches and significant advancements in nicotine treatment.
Lake Street 9th Annual Best Ideas Growth Conference (BIG9)
On September 11, Achieve Life Sciences will also participate in one-on-one meetings during the Lake Street BIG9 conference, aimed at forging deeper relationships with potential investors and partners.
About Achieve Life Sciences, Inc.
Achieve Life Sciences is dedicated to tackling the global nicotine dependence challenge through the development and commercialization of cytisinicline, a promising treatment model. With the submission of its New Drug Application to the FDA for cytisinicline, Achieve is on the brink of a significant breakthrough in smoking cessation.
This initiative is underpinned by two successfully completed Phase 3 studies and a fully enrolled open-label safety study. Moreover, the company is progressing with a Phase 2 study addressing vaping cessation, marking a holistic approach to nicotine product dependency.
The Impact of Cytisinicline
Currently, there are approximately 29 million adults in the nation who smoke conventional cigarettes. The toll of tobacco use is staggering, being the primary cause of preventable death globally, contributing to over eight million fatalities each year, with nearly half a million occurring within the United States. This alarming mortality rate highlights the urgency of effective cessation strategies.
Furthermore, e-cigarette usage is also a growing concern, with around 17 million U.S. adults identified as users. Recent statistics revealed that approximately 1.6 million middle and high school students reported using e-cigarettes, emphasizing the critical need for approved treatment options in this area. Cytisinicline has received Breakthrough Therapy designation from the FDA, signifying its potential to fulfill this unmet need.
Understanding Cytisinicline
Cytisinicline, a plant-derived alkaloid, exhibits a strong binding affinity to the nicotinic acetylcholine receptor. This compound plays a vital role in mitigating nicotine addiction symptoms, significantly contributing to the treatment of both smoking and vaping cessation. By interacting with brain receptors, cytisinicline aims to alleviate the intensity of nicotine cravings while diminishing the pleasure derived from nicotine products.
It's essential to note that while cytisinicline shows promise as an investigational product candidate in managing nicotine dependence, it has not yet been granted approval by the FDA for any specific indication in the United States.
Contact for Investors
For additional details on these investor relations opportunities or to schedule meetings, please reach out directly through Achieve Life Sciences' Investor Relations:
Nicole Jones
Achieve Life Sciences, Inc.
Email: ir@achievelifesciences.com
Phone: 425-686-1510
Frequently Asked Questions
What is Achieve Life Sciences focused on?
Achieve Life Sciences specializes in developing treatments for nicotine dependence, particularly through cytisinicline.
What notable conferences is Achieve Life Sciences attending?
Achieve is participating in the H.C. Wainwright 27th Annual Global Investment Conference and the Lake Street 9th Annual Best Ideas Growth Conference.
What is cytisinicline?
Cytisinicline is a plant-based compound being developed for treating nicotine addiction and facilitating smoking cessation.
Is cytisinicline FDA approved?
No, cytisinicline is currently an investigational product and has not yet received FDA approval for any specific indication.
How can investors contact Achieve Life Sciences?
Investors can reach Nicole Jones, the company's contact person for investor relations, via email at ir@achievelifesciences.com or by phone at 425-686-1510.
